If you bet $100 on Axovant Sciences nine months ago, you’re down 93 bucks. But the biotech company best known for a blowup rivaling bitcoin wants a second chance, and on Wednesday is unveiling new management and a new drug it believes can win investors back over.

Axovant, founded by biotech entrepreneur Vivek Ramaswamy, is pivoting to gene therapy. The company paid $30 million up front for a one-time treatment Axovant believes could change the lives of patients with Parkinson’s disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ramaswamy is the champion of an ever growing population of biotech con men. Promise the next big thing in biotech, find fools willing to give money, when that thing fails miserably, move to the next promise. While hiding some cash and living large in the process.
    Nathaniel David is another good example, although more sophisticated.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy